Structure Therapeutics (GPCR) Total Current Liabilities (2022 - 2026)
Structure Therapeutics (GPCR) posted quarterly Total Current Liabilities of $57.0 million for Q1 2026, up 56.18% year-over-year from $36.5 million in Q1 2025, and down 9.96% quarter-over-quarter from $63.3 million in Q4 2025.
Structure Therapeutics (GPCR) Total Current Liabilities (2022 - 2026) Analysis & Trends
Structure Therapeutics' Total Current Liabilities history runs 5 years deep, the most recent figure standing at $57.0 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 56.18% year-over-year to $57.0 million; the TTM figure through Mar 2026 stood at $57.0 million (up 56.18% YoY), while the FY2025 annual figure was $63.3 million, up 75.69% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $57.0 million, down from $63.3 million in the prior quarter.
- The five-year high for Total Current Liabilities was $63.3 million in Q4 2025, with the low at $11.0 million in Q1 2023.
- The 5-year median for Total Current Liabilities is $29.1 million (2023), against an average of $32.3 million.
- Peak annual rise in Total Current Liabilities reached 114.38% in 2024, while the deepest fall reached 45.6% in 2024.
- Structure Therapeutics' Total Current Liabilities stood at $13.0 million in 2022, then jumped by 90.16% to $24.7 million in 2023, then soared by 45.6% to $36.0 million in 2024, then surged by 75.69% to $63.3 million in 2025, then declined by 9.96% to $57.0 million in 2026.
- Business Quant data shows GPCR's Total Current Liabilities at $57.0 million in Q1 2026, $63.3 million in Q4 2025, and $57.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Structure Therapeutics | 11.65 Bn | 11.65 Bn | - | 66.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 66.11 Mn |
| Mar 31, 2026 | 56.98 Mn |
| Dec 31, 2025 | 63.29 Mn |
| Sep 30, 2025 | 57.53 Mn |
| Jun 30, 2025 | 39.03 Mn |
| Mar 31, 2025 | 36.49 Mn |
| Dec 31, 2024 | 36.02 Mn |
| Sep 30, 2024 | 33.43 Mn |
| Jun 30, 2024 | 22.66 Mn |
| Mar 31, 2024 | 23.59 Mn |
| Dec 31, 2023 | 24.74 Mn |
| Sep 30, 2023 | 20.09 Mn |
| Jun 30, 2023 | 15.01 Mn |
| Mar 31, 2023 | 11.00 Mn |
| Dec 31, 2022 | 13.01 Mn |